Clarity is GenoLogics' laboratory information management system built especially for the needs of clinical or research genomics and mass spec labs to provide end-to-end sample tracking, automation, preconfigured workflows, and superior usability.
With the use of Clarity LIMS, Macrogen aims to strengthen its support for researchers and clinical customers by automating the analysis of whole-genome sequencing and clinical sequencing services, as well as by systematically managing the strict requirements of clinical environments.
Earlier this year, in January, Macrogen became an early adopter of US genetic variation and function analysis specialist Illumina's (NASDAQ:ILMN) HiSeq X Ten platform to pioneer new diagnostic and genomics services and strengthen the foundation for personalised medicine. The company also introduced the X-Genome (Xpressway to Genome) service for researchers who carry out large-scale whole-human genome sequencing based trials.
Furthermore, Macrogen has established a US subsidiary, Macrogen Clinical Laboratory, Inc. (MCL), which opened a CLIA (Clinical Laboratory Improvement Amendments)-certified clinical lab last year to provide clinical sequencing based healthcare services for physicians and patients. It is in its MCL subsidiary that Macrogen plans to use Clarity LIMS first.
As GenoLogics' CEO, Michael Ball, explained, Clarity LIMS enhances the overall efficiency and results of genome research.
Macrogen's CEO, Kim Hyung-tae, said that the US subsidiary MCL selected GenoLogics' Clarity LIMS after recognising that it is the optimum means of providing whole-genome sequencing services in close cooperation with the Korean Headquarters while satisfying the stringent requirements of CLIA. The X-Genome service, based on the HiSeq X Ten system for whole-human genome sequencing, will help Macrogen boost its competitive edge in the existing research market and establish a leading position in the clinical sequencing service market, Hyung-tae added.
Perrigo to acquire United States rights for Entocort from AstraZeneca
US FDA approves Boehringer Ingelheim's Pradaxa
Phase II clinical trial for potential treatment of androgenetic alopecia completed by Samumed
Life Sciences Partners collaborates on immuno-oncology with Bristol-Myers Squibb
Arsanis initiates first cohort in Phase one clinical trial of ASN100
Impax introduces generic Avodart (Dutasteride) Capsules, 0.5 mg
Mylan unveils generic FazaClo orally disintegrating tablets for treating schizophrenia